Interplay of OpdP Porin and Chromosomal Carbapenemases in the Determination of Carbapenem Resistance/Susceptibility in Pseudomonas aeruginosa.
Anti-Bacterial Agents
/ pharmacology
Bacterial Proteins
/ genetics
Carbapenems
/ pharmacology
Chromosomes, Bacterial
/ enzymology
Drug Resistance, Bacterial
Humans
Microbial Sensitivity Tests
Porins
/ genetics
Pseudomonas Infections
/ microbiology
Pseudomonas aeruginosa
/ drug effects
beta-Lactamases
/ genetics
OpdP porin
OprD
PDC AmpC variants
PoxB oxacillinase
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
31 10 2021
31 10 2021
Historique:
pubmed:
30
9
2021
medline:
1
2
2022
entrez:
29
9
2021
Statut:
ppublish
Résumé
Carbapenem resistance in Pseudomonas aeruginosa strains responsible for chronic lung infections in cystic fibrosis (CF) patients is mainly due to loss of the OprD protein and, limited to meropenem and doripenem, to overexpression of efflux pumps. However, recent reports of isolates showing inconsistent genotype-phenotype combinations (e.g., susceptibility in the presence of resistance determinants and vice versa) suggest the involvement of additional factors whose role is not yet fully elucidated. Among them, the OpdP porin as an alternative route of entry for carbapenems other than OprD and the overexpression of two chromosomal carbapenemases, the Pseudomonas-derived cephalosporinase (PDC) and the PoxB oxacillinase, have recently been reconsidered and studied in specific model strains. Here, the contribution of these factors was investigated by comparing different phenotypic variants of three strains collected from the sputum of colonized CF patients. Carbapenem uptake through OpdP was investigated both at the functional level, by assessing the competition exerted by glycine-glutamate, the OpdP's natural substrate, against imipenem uptake, and at the molecular level, by comparing the expression levels of
Identifiants
pubmed: 34585948
doi: 10.1128/Spectrum.01186-21
pmc: PMC8557820
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
Carbapenems
0
Porins
0
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0118621Références
Future Microbiol. 2015;10(2):231-9
pubmed: 25689535
Pathology. 2015 Feb;47(2):156-60
pubmed: 25551306
APMIS. 2015 Dec;123(12):1061-8
pubmed: 26522829
Gene. 2005 Sep 26;358:82-92
pubmed: 16120476
Chem Biol. 2015 Apr 23;22(4):535-547
pubmed: 25910245
Trends Microbiol. 2016 May;24(5):327-337
pubmed: 26946977
Antimicrob Agents Chemother. 2006 May;50(5):1633-41
pubmed: 16641429
Antimicrob Agents Chemother. 2001 Jun;45(6):1780-7
pubmed: 11353625
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Clin Microbiol. 2006 Jul;44(7):2348-53
pubmed: 16825348
FEMS Microbiol Lett. 2006 Jul;260(1):23-9
pubmed: 16790014
ACS Chem Biol. 2017 Jun 16;12(6):1656-1664
pubmed: 28440622
APMIS. 2007 Aug;115(8):891-9
pubmed: 17696944
J Antimicrob Chemother. 2009 Aug;64(2):294-300
pubmed: 19468029
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents
pubmed: 17630334
Microorganisms. 2016 Aug 10;4(3):
pubmed: 27681920
Antimicrob Agents Chemother. 2015 Jan;59(1):427-36
pubmed: 25367914
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192
pubmed: 30500353
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6735-6741
pubmed: 27572406
Int J Antimicrob Agents. 2018 Sep;52(3):358-364
pubmed: 29775685
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6726-6734
pubmed: 27572404
Int J Med Microbiol. 2017 Sep;307(6):353-362
pubmed: 28754426
Int J Antimicrob Agents. 2016 Dec;48(6):740-743
pubmed: 28128097
Antimicrob Agents Chemother. 2009 May;53(5):1766-71
pubmed: 19258272
FEMS Microbiol Lett. 2018 Mar 1;365(6):
pubmed: 29401362
Antimicrob Agents Chemother. 2015 Nov 30;60(2):936-45
pubmed: 26621621